Rebecca S. Heist, MD
Results from a single-arm, multicenter trial showed that the antibody-drug conjugate sacituzumab govitecan (IMMU-132) was well-tolerated and produced a median duration of response of 6.0 months in previously treated patients with metastatic non–small cell lung cancer (NSCLC).1
The investigators wrote that immunohistochemistry staining of tumor specimens did not produce enough evidence to determine whether Trop-2 staining is a useful biomarker for predicting response.
- Heis RS, Guarino MJ, Masters G, et al. Therapy of advanced non–small-cell lung cancer with an SN-38-anti-trop-2 drug conjugate, sacituzumab govitecan [published online May 26, 2017]. J Clin Oncol. doi: 10.1200/JCO.2016.72.1894.
- Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015;21(17):3870-3878. doi: 10.1158/1078-0432.CCR-14-3321.
... to read the full story